We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M Turnover 60.61%
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
Cap. Flow
+$2.99M
Cap. Flow %
4.5%
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.2 years

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$3.53M
2
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$2.94M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.18M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$1.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.37M

Top Sells

Rank Stock Value
1
GIS icon
General Mills
GIS
+$2.52M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$2.31M
3
AMGN icon
Amgen
AMGN
+$2.08M
4
ABT icon
Abbott
ABT
+$1.72M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.56M

Sector Composition

Rank Sector Weight
1 Healthcare 43.45%
2 Miscellaneous 41.8%
3 Consumer Discretionary 7.1%
4 Consumer Staples 6.25%
5 Communication Services 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GWPH
1
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.74M 5.64%
36,847
+3,290
+10% +$352K
2017 Q1
2 quarters
INCY icon
2
Incyte
INCY
$23.6B
$3.26M 4.91%
+27,887
New +$3.53M
2017 Q3
0 quarters
TEVA icon
3
Teva Pharmaceutical Industries Limited
TEVA
$47.6B
$2.3M 3.47%
+130,723
New +$2.94M
2017 Q3
0 quarters
ALNY icon
4
CALL
Alnylam Pharmaceuticals
ALNY
$30.9B
$2.1M 3.17%
+101,100
New +$8.63M
2017 Q3
0 quarters
TSRO
5
DELISTED
TESARO, Inc.
TSRO
$1.87M 2.81%
14,462
+3,657
+34% +$454K
2017 Q2
1 quarter
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$1.8M 2.71%
21,787
-19,713
-48% -$1.56M
2017 Q1
2 quarters
BABA icon
7
Alibaba
BABA
$270B
$1.71M 2.58%
9,900
– –
2016 Q2
5 quarters
VRTX icon
8
CALL
Vertex Pharmaceuticals
VRTX
$130B
$1.59M 2.4%
65,500
+6,500
+11% +$978K
2016 Q4
3 quarters
CLVS
9
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$1.56M 2.36%
84,200
-61,000
-42% -$4.84M
2017 Q1
2 quarters
AKBA icon
10
CALL
Akebia Therapeutics
AKBA
$171M
$1.45M 2.19%
190,400
+39,100
+26% +$601K
2015 Q4
7 quarters
PBYI icon
11
Puma Biotechnology
PBYI
$555M
$1.37M 2.06%
+11,438
New +$1.06M
2017 Q3
0 quarters
TSRO
12
PUT
DELISTED
TESARO, Inc.
TSRO
$1.34M 2.03%
31,000
-4,000
-11% -$497K
2016 Q2
5 quarters
KITE
13
CALL
DELISTED
Kite Pharma, Inc.
KITE
$1.32M 2%
103,200
+77,900
+308% +$10.9M
2016 Q3
4 quarters
GWPH
14
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.32M 1.99%
71,000
+17,400
+32% +$1.86M
2015 Q4
7 quarters
PLCE icon
15
Children's Place
PLCE
$23.6M
$1.3M 1.96%
+11,000
New +$1.18M
2017 Q3
0 quarters
INSM icon
16
CALL
Insmed
INSM
$20.9B
$1.28M 1.93%
222,000
+152,000
+217% +$2.9M
2016 Q1
6 quarters
IBB icon
17
iShares Biotechnology ETF
IBB
$10.9B
$1.22M 1.84%
10,986
-9,255
-46% -$989K
2017 Q1
2 quarters
ICPT
18
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.18M 1.77%
+20,264
New +$2.18M
2017 Q3
0 quarters
KMB icon
19
Kimberly-Clark
KMB
$36B
$1.14M 1.72%
+9,700
New +$1.18M
2017 Q3
0 quarters
NKE icon
20
Nike
NKE
$56.3B
$1.06M 1.59%
+20,400
New +$1.15M
2017 Q3
0 quarters
BMY icon
21
CALL
Bristol-Myers Squibb
BMY
$126B
$1.02M 1.54%
116,800
+60,300
+107% +$3.52M
2017 Q1
2 quarters
HSIC icon
22
Henry Schein
HSIC
$9.44B
$1.01M 1.53%
+15,744
New +$1.07M
2017 Q3
0 quarters
ZGNX
23
DELISTED
Zogenix, Inc.
ZGNX
$939K 1.42%
+26,778
New +$363K
2017 Q3
0 quarters
GILD icon
24
Gilead Sciences
GILD
$194B
$938K 1.41%
+11,581
New +$886K
2017 Q3
0 quarters
ALXN
25
DELISTED
Alexion Pharmaceuticals
ALXN
$914K 1.38%
+6,518
New +$886K
2017 Q3
0 quarters
1
2 3 4 5

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2017 Portfolio in Review

As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

FT Options deployed $2.99M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.

  • FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
  • FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
  • FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
  • FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
  • FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
  • FT Options opened 108 new positions and closed 72 in Q3 2017.
  • FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.